SNS Insider Highlights U.S. Neuropathic Pain Market Growth, Projected to Reach USD 5.47 Billion by 2033, Supported by Advanced Healthcare Systems, Innovative Pain Management Solutions, and Strong Reimbursement Pathways.
Austin, Dec. 02, 2025 (GLOBE NEWSWIRE) — Neuropathic Pain Market Size & Growth
According to SNS Insider, the Neuropathic Pain Market is estimated at $8.15 billion in 2025 and is expected to reach $15.37 billion by 2033, reflecting a CAGR of 8.29% during 2026 to 2033. Growth is driven by the increasing number of patients with diabetes and cancer, the rising burden of chronic pain, the introduction of next-generation drugs, and the adoption of digital tools for remote pain monitoring.
The U.S. Neuropathic Pain Market size is estimated at $2.95 Billion in 2025 and is forecasted to reach $5.47 Billion by 2033, growing at a CAGR of 8.07% over the forecast period of 2026-2033, due to high prevalence of diabetes and cancer, advanced healthcare infrastructure, strong patient awareness, widespread adoption of innovative therapies, and supportive reimbursement policies, driving extensive access to effective neuropathic pain treatments nationwide.
Request a Free Sample Report for the Neuropathic Pain Market: https://www.snsinsider.com/sample-request/8959
Neuropathic Pain Market Report Scope
| Report Attributes | Details |
| Market Size in 2025E | USD 8.15 Billion |
| Market Size by 2033 | USD 15.37 Billion |
| CAGR | CAGR of 8.29% From 2026 to 2033 |
| Base Year | 2025E |
| Forecast Period | 2026-2033 |
| Historical Data | 2022-2024 |
| Key Segments | • By Drug Class (Anticonvulsants, Tricyclic Antidepressants (TCA), Opioids, Capsaicinoids, Others) • By Application (Diabetic Neuropathy, Chemotherapy Induced Neuropathy, Sciatic Neuropathy, Others) • By Route of Administration (Oral, Parenteral) • By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Segment Analysis:
By Drug Class
Anticonvulsants led the market with a share of 35.20% as they have been proved effective in stabilization of nerve activity and reduction of abnormal pain signaling. Tricyclic Antidepressants (TCA) is the fastest-growing segment with a CAGR of 8.50% driven by their acquitted performance in treating chronic neuropathic symptoms and dual mechanism of action involving serotonin and norepinephrine reuptake inhibition.
By Application
In 2025, Chemotherapy Induced Neuropathy led the market with a share of 40.30% driven by increasing number of cancer patients who receive chemotherapy that further leads to nerve damage and chronic pain. Diabetic Neuropathy is the fastest-growing segment with a CAGR of 9.20% due to the increasing awareness, early diagnosis and advent of efficient treatment options for diabetic patients.
By Route of Administration
In 2025, Oral led the market with a share of 70.20% due to its convenience, patient compliance and heavy use of medications including anticonvulsants and antidepressants. Parenteral is the fastest-growing segment with a CAGR of 7.80% due to the growing adoption of injectable therapies for intense and refractory neuropathic pain.
By Distribution Channel
In 2025, Retail Pharmacy led the market with a share of 55.10% owing to its wide network, customer confidence, and ease of access for the patient’s need of prescription medicines used in chronic pain therapies. Online Pharmacy is the fastest-growing segment with a CAGR of 12.04% driven by growing e-commerce penetration, convenience of home delivery and emergence of telemedicine platforms.
Need Any Customization Research on Neuropathic Pain Market, Enquire Now: https://www.snsinsider.com/enquiry/8959
Regional Insights:
The North America dominated the Neuropathic Pain Market in 2025E, with over 50.20% revenue share, due to high prevalence of diabetes, cancer and aging population with neuropathic conditions.
The Asia Pacific region is expected to have the fastest-growing CAGR 9.66%, owing to increasing incidences of diabetes, cancer and increased aged population.
Key Neuropathic Pain Companies Profiled in the Report
- Pfizer Inc.
- Eli Lilly and Company
- Johnson and Johnson
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Grünenthal GmbH
- UCB S.A.
- Sanofi S.A.
- Biogen Inc.
- Astellas Pharma Inc.
- Vertex Pharmaceuticals Incorporated
- Aptinyx Inc.
- Daiichi Sankyo Company, Limited
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Mallinckrodt Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- Assertio Therapeutics, Inc.
- Ipsen
- Endo International plc
Recent Developments:
- In June 2025, Sun Pharmaceutical, launched a generic version of Gabapentin in Canada. Gabapentin is an anticonvulsant medication used to treat neuropathic pain and epilepsy, expanding Sun Pharma’s presence in the neuropathic pain market.
- In May 2025, Biogen partnered with Stoke Therapeutics to develop zorevunersen for Dravet syndrome, a severe form of epilepsy, which may involve neuropathic pain components.
Purchase Single User PDF of Neuropathic Pain Market Report: https://www.snsinsider.com/checkout/8959
Exclusive Sections of the Report (The USPs):
- PATIENT ADHERENCE & COMPLIANCE METRICS – helps you understand real-world treatment continuity by tracking medication adherence levels, drop-off rates due to side effects or cost, and patient preferences for oral vs topical therapies.
- TREATMENT EFFECTIVENESS & RESPONSE SCORE – helps you evaluate therapeutic success by analyzing average pain-relief outcomes, time required for symptom improvement, and patient switching rates driven by drug inefficacy.
- PRESCRIPTION BEHAVIOR & PHYSICIAN PREFERENCE INDEX – helps you identify prescribing trends by assessing combination therapy usage, generic-to-branded switching patterns, and specialty-wise preference for specific drug classes.
- ACCESSIBILITY & CARE DELIVERY LANDSCAPE – helps you measure treatment reach by comparing urban vs rural drug availability, telemedicine adoption for neuropathic pain consultations, and pharmacy density across regions.
- MARKET RESPONSE & PATIENT MANAGEMENT INSIGHTS – helps you uncover unmet needs by correlating adherence gaps, switching behaviors, and therapy effectiveness with opportunities for new formulations or digital patient-support tools.
Related Reports
Peripheral Neuropathy Market
Pain Management Market
Diabetic Neuropathy Market
Antidepressants Market
Analgesics Market
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.